Logotype for BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals (BCRX) investor relations material

BioCryst Pharmaceuticals M&A Announcement summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for BioCryst Pharmaceuticals Inc
M&A Announcement summary14 Oct, 2025

Deal rationale and strategic fit

  • Acquisition adds navenibart, a late-stage, long-acting injectable HAE therapy, supporting a rare disease growth strategy and double-digit revenue growth over the next decade.

  • Expands the HAE portfolio with both oral and injectable therapies, covering a full spectrum of patient preferences and addressing unmet needs for less frequent dosing.

  • Seamlessly integrates into and complements the existing HAE franchise, leveraging established commercialization infrastructure.

  • Accelerates product diversification and reinforces commitment to the HAE community.

  • Combined portfolio expected to transform growth profile and reinforce leadership in HAE.

Financial terms and conditions

  • Total enterprise value of $700 million and implied aggregate equity value of $920 million, with Astria shareholders receiving $8.55 in cash and 0.59 BioCryst shares per Astria share, implying $13.00 per share and a 53% premium to prior close.

  • Astria stockholders will own about 15% of the combined company.

  • The acquisition will be financed through a mix of equity, cash on hand, and a Blackstone facility ($400–$550 million).

  • Sale of the European business and retirement of $200 million Pharmakon debt improves the balance sheet.

  • Transaction expected to be significantly accretive to operating profit in the first full year after navenibart's launch.

Synergies and expected cost savings

  • Significant operational and long-term synergies expected, leveraging existing commercialization infrastructure.

  • Minimal incremental SG&A investment anticipated due to established commercial engine.

  • Enhanced financial profile with strong cash flow generation and profitability maintained post-transaction.

  • Accelerated revenue from navenibart projected to boost earnings growth well into the next decade.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next BioCryst Pharmaceuticals earnings date

Logotype for BioCryst Pharmaceuticals Inc
Q3 20253 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next BioCryst Pharmaceuticals earnings date

Logotype for BioCryst Pharmaceuticals Inc
Q3 20253 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

BioCryst Pharmaceuticals Inc develops and commercializes oral medications for rare and serious diseases. The company focuses on small-molecule therapeutics, including treatments for hereditary angioedema and viral infections. Its research pipeline supports expansion into additional indications. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage